Lonza invests in high potent API capabilities

Contract development manufacturing organisation (CDMO) Lonza is expanding its highly potent API (HPAPI) capacity in order to meet increased market demand.

Lonza will invest in two multi-purpose production lines for HPAPI manufacturing at its Visp site in Switzerland. Lonza will also optimise capacity to improve  its flexibility in existing production lines, supporting shorter time-to-market and accelerated approval timelines for partners.

The expansion is being made alongside a manufacturing agreement with AstraZeneca through which the facility will support the delivery of a number of products.

“We are delighted to support one of our strategic partners in securing supply of innovative therapies for the treatment of cancer patients,” said Lee Newton, VP and API business unit head, Lonza Pharma & Biotech. “Oncology continues as the leading indication in biopharma and we will continue to invest to meet the HPAPI development and manufacturing needs of our customers.”

“We listen to our customers and understand that needs vary more than ever in the biopharma space”, commented Gordon Bates, president Chemical Division, Lonza Pharma & Biotech. “We have invested accordingly in both technology and scale to ensure that we enable our customers to bring new medicines to patients faster. Our creative suite of tailored business models are also key in partnering for success."